Why GlaxoSmithKline (GSK) Stock Is Down Today Shares of GlaxoSmithKline (GSK) are down after reports that they face a criminal probe in the U.K. after allegations in China that the drugmaker's employees bribed doctors, hospitals and medical associations to increase sales. Tedd Cohen May 28, 2014 12:30 PM EDT
Full Answer
Why is the GSK share price down 6%?
GSK share price down after profit warning due to R&D spending GlaxoSmithKline has seen its share price tumble more than 6% in the days following its full-year results, with investors pulling back after the company warned that profits will suffer as it ramps up R&D spending.
How can I get the latest news about GSK?
Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Why has GSK split into two companies?
The decision to divide the company in two came at the end of 2018 after GSK announced a £9.8 billion consumer health joint venture with US rival Pfizer.
Is GlaxoSmithKline (GSK) overvalued?
The P/E ratio of GlaxoSmithKline is 18.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 19.15. GlaxoSmithKline has a PEG Ratio of 2.49. PEG Ratios above 1 indicate that a company could be overvalued. GlaxoSmithKline has a P/B Ratio of 4.45.
Will GSK stock go up?
Over the next 52 weeks, GlaxoSmithKline PLC has on average historically risen by 14.8% based on the past 44 years of stock performance.
Is GSK a good stock to buy?
GSK plc (ADR)'s trailing 12-month revenue is $44.3 billion with a 14.0% profit margin. Year-over-year quarterly sales growth most recently was 31.8%. Analysts expect adjusted earnings to reach $3.230 per share for the current fiscal year. GSK plc (ADR) currently has a 4.8% dividend yield.
What are prospects for GSK shares worth?
GSK plc (NYSE:GSK) The 17 analysts offering 12-month price forecasts for GSK plc have a median target of 45.02, with a high estimate of 55.64 and a low estimate of 35.41.
Is GlaxoSmithKline a buy Zacks?
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return4Sell5.79%5Strong Sell2.83%S&P50011.24%3 more rows
Is GSK shutting down?
GSK says businesses in Ulverston, Cumbria, and Barnard Castle, County Durham, will close by 2025.
What will happen to GSK shares when the company splits?
Glaxo aims to complete the demerger and listing of its consumer healthcare business, Haleon, by July 18th. Investors will receive one share in Haleon for every existing Glaxo share they own, leaving the pharmaceutical company's investors owning 54.5% of the new business.
Is GSK overvalued?
Based on the current valuation, I consider GSK overvalued to a $42/share price.
Why is Glaxo price rising?
Glaxo's sales for the period rose by 10% to £9.1bn, while earnings were 3% higher. The rebound was led by a 41% increase in sales of shingles vaccine Shingrix. Broker forecasts suggest GSK's earnings will rise by a further 8% in 2022.
When did GSK split?
A circular is expected to be sent to shareholders in connection with approval of the proposed demerger in June 2022, alongside publication of a prospectus in connection with the listing of Haleon. A shareholder vote for approval and subsequent demerger is expected in July 2022.
Is Pfizer stock a buy Zacks?
Zacks' proprietary data indicates that Pfizer Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the PFE shares relative to the market in the next few months.
Is GSK a good company to work for?
Glassdoor rating: 3.9 Other GSK Glassdoor reviews spoke highly of training and development and compensation/benefits, and 76% of current employees would recommend GSK as a place to work. An impressive 85% of employees approve of GSK's CEO, Emma Walmsley - the first female CEO to run a top 10 pharmaceutical company.
Should I buy or sell GSK stock right now?
9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 1 sell rating,...
How has GSK's stock price performed in 2022?
GSK's stock was trading at $44.10 on January 1st, 2022. Since then, GSK stock has decreased by 0.7% and is now trading at $43.80. View the best gr...
Are investors shorting GSK?
GSK saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 6,020,000 shares, a decline of 18.1%...
When is GSK's next earnings date?
GSK is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022. View our earnings forecast for GSK .
How were GSK's earnings last quarter?
GSK plc (NYSE:GSK) issued its quarterly earnings results on Wednesday, April, 27th. The pharmaceutical company reported $0.88 earnings per share (E...
How often does GSK pay dividends? What is the dividend yield for GSK?
GSK announced a quarterly dividend on Wednesday, May 4th. Stockholders of record on Friday, May 20th will be given a dividend of $0.3496 per share...
Is GSK a good dividend stock?
GSK(NYSE:GSK) pays an annual dividend of $1.37 per share and currently has a dividend yield of 3.18%. The dividend payout ratio of GSK is 49.46%. T...
Who are GSK's key executives?
GSK's management team includes the following people: Ms. Emma N. Walmsley , CEO & Director (Age 52, Pay $4.88M) Mr. Iain James Mackay , CFO & E...
Who are some of GSK's key competitors?
Some companies that are related to GSK include Eli Lilly and (LLY) , Pfizer (PFE) , Roche (RHHBY) , AbbVie (ABBV) , Merck & Co., Inc. (MRK) ,...
What's GSK Pharma share price today and what are GSK Pharma share returns ?
As on 10 Jun, 2022, 03:54 PM IST GSK Pharma share price was up by 0.51% basis the previous closing price of Rs 1,511.7. GSK Pharma share price was...
What's the market capitalization of GSK Pharma?
Within the Pharmaceuticals sector, GSK Pharma stock has a market cap rank of 14. GSK Pharma has a market cap of Rs 26,211.35 Cr.
Should I buy, sell or hold GSK Pharma?
As per Refinitiv (erstwhile Thomson Reuters), overall mean recommendation by 7 analysts for GSK Pharma stock is to Hold. Recommendation breakup is...
What has been highest price of GSK Pharma share in last 52 weeks?
In last 52 weeks GSK Pharma share had a high price of Rs 1,918.75 and low price of Rs 1,450.00
Who are peers to compare GSK Pharma share price?
Top 5 Peers for GSK Pharma are Pfizer Ltd., Sanofi India Ltd., Abbott India Ltd., AstraZeneca Pharma India Ltd. and Procter & Gamble Health Ltd.
Who are the key owners of GSK Pharma stock?
Promoter,DII and FII owns 75.0, 5.7 and 7.08 shares of GSK Pharma as on 31 Mar 2022There is no change in promoter holding from 31 Dec 2021 to 31 Ma...
What are the key metrics to analyse GSK Pharma Share Price?
Key Metrics for GSK Pharma are: PE Ratio of GSK Pharma is 15.47 Earning per share of GSK Pharma is 100.04 Price/Sales ratio of GSK Pharma is 8.59 P...
What is GlaxoSmithKline Pharmaceuticals?
GlaxoSmithKline Pharmaceuticals Ltd., incorporated in the year 1924, is a Large Cap company (having a market cap of Rs 25,359.24 Crore) operating in Pharmaceuticals sector. GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2021.
What is the ranking of a company within its sector based on?
This is the ranking of a company within its sector based on MCap or Market capitalization. Higher the market capitalization of a company, higher the rank it is assigned.
What is face value of stock?
Face value of a stock is the value ascribed to the stock as per the balance sheet of the company. The dividend declared by a company is usually declared as a percentage of face value. (₹) 10.00.
What is a stock score?
Stock Score is the Average Score from Stock Reports Plus by Refinitiv which combines quantitative analysis of widely used investment decision making tools. This score is on a 10 point scale (1 is lowest and 10 being the highest, NR indicates No-rating is available)
How much does GlaxoSmithKline pay Alector?
(Bloomberg) -- GlaxoSmithKline Plc agreed to pay U.S. biotech Alector Inc. as much as $2.2 billion to develop therapies targeting diseases such as Parkinson’s and Alzheimer’s, the latest step by the U.K. pharmaceutical giant to rebuild its drug pipeline.Alector will receive $700 million upfront from Glaxo, and up to $1.5 billion in the future if the treatments prove successful, the companies said Friday. They will co-develop and commercialize two monoclonal antibodies, one of which is in late-st
What is the LH acquisition of Toxikon?
LabCorp's (LH) acquisition of Toxikon can expand its full-service drug development and medical device solutions portfolio.
Do pharmaceutical stocks pay dividends?
When it comes to dividend investing, pharmaceutical stocks can be quite appealing. Because they can count on a regular volume of sales for their established medicines, they tend to have a bottom line that is stable enough to pay out dividends for years and years. Today, I'll be looking at two such pharma businesses that are both undervalued and that don't skimp on the dividend.
Is GSK a late stage drug?
GSK said on Friday its anaemia drug for patients with kidney disease succeeded in late-stage trials, marking an important milestone for the British drugmaker as it bolsters its pipeline ahead of a split with its consumer healthcare venture.
Is GlaxoSmithKline a pharmaceutical company?
Analyst Report: GlaxoSmithKline plc In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.
When will GSK earnings call end?
GSK earnings call for the period ending September 30, 2021.
Who is the CEO of GlaxoSmithKline?
Amid an assault from activist investors, GlaxoSmithKline CEO Emma Walmsley said the company's third-quarter financial results show that her strategy is on the right track.
Is GlaxoSmithKline a pharmaceutical company?
Analyst Report: GlaxoSmithKline plc In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.
When will GSK earnings call end?
GSK earnings call for the period ending June 30, 2021.
How much did GlaxoSmithKline stock drop in 2016?
Is GlaxoSmithKline's Stock a Bargain After Dropping 4.8% in 2016?
Who does GlaxoSmithKline take on?
GlaxoSmithKline takes on Pfizer, and Biogen battles Celgene in this healthcare edition of Industry Focus.
How many articles has The Fool written on GlaxoSmithKline?
The Fool has written over 1000 articles on GlaxoSmithKline.
When did GSK split?
The decision to divide the company in two came at the end of 2018 after GSK announced a £9.8 billion consumer health joint venture with US rival Pfizer.
Can you short GSK with IG?
You can go long or short GSK with IG using derivatives like CFDs and spread bet s.
